Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Adrenal Cortex Neoplasms
/ genetics
Adrenocortical Carcinoma
/ genetics
Animals
Cell Proliferation
/ genetics
Disease Models, Animal
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
Humans
Kaplan-Meier Estimate
Mice, Knockout
Mice, Transgenic
Prognosis
Tumor Suppressor Protein p53
/ genetics
Wnt Signaling Pathway
/ genetics
beta Catenin
/ genetics
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
29
02
2020
accepted:
04
06
2020
revised:
28
05
2020
pubmed:
21
6
2020
medline:
1
12
2020
entrez:
21
6
2020
Statut:
ppublish
Résumé
Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with limited therapeutic options. The lack of mouse models that recapitulate the genetics of ACC has hampered progress in the field. We analyzed The Cancer Genome Atlas (TCGA) dataset for ACC and found that patients harboring alterations in both p53/Rb and Wnt/β-catenin signaling pathways show a worse prognosis compared with patients that harbored alterations in only one. To model this, we utilized the Cyp11b2(AS)
Identifiants
pubmed: 32561853
doi: 10.1038/s41388-020-1358-5
pii: 10.1038/s41388-020-1358-5
pmc: PMC7378041
mid: NIHMS1601261
doi:
Substances chimiques
CTNNB1 protein, human
0
Tumor Suppressor Protein p53
0
beta Catenin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5282-5291Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK100653
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK123694
Pays : United States
Références
Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282–326.
pubmed: 24423978
Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551–64.
pubmed: 24081734
Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger RR, et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179:G1–46.
pubmed: 30299884
Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99:455–61.
pubmed: 24302750
Mohan DR, Lerario AM, Hammer GD. Therapeutic targets for adrenocortical carcinoma in the genomics era. J Endocr Soc. 2018;2:1259–74.
pubmed: 30402590
pmcid: 6215083
Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, et al. Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018;103:4511–23.
pubmed: 30113656
Leccia F, Batisse-Lignier M, Sahut-Barnola I, Val P, Lefrançois-Martinez AM, Martinez A. Mouse models recapitulating human adrenocortical tumors: what is lacking? Front Endocrinol. 2016;7:93.
Basham KJ, Hung HA, Lerario AM, Hammer GD. Mouse models of adrenocortical tumors. Mol Cell Endocrinol. 2016;421:82–97.
pubmed: 26678830
Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607–12.
pubmed: 24747642
Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723–36.
pubmed: 27165744
pmcid: 4864952
Ragazzon B, Libé R, Gaujoux S, Assié G, Fratticci A, Launay P, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010;70:8276–81.
pubmed: 20959480
Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, Louiset E, et al. Constitutive β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet. 2010;19:1561–76.
pubmed: 20106872
Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol. 2012;181:1017–33.
pubmed: 22800756
pmcid: 3432433
Basham KJ, Rodriguez S, Turcu AF, Lerario AM, Logan CY, Rysztak MR, et al. A ZNRF3-dependent Wnt/β-catenin signaling gradient is required for adrenal homeostasis. Genes Dev. 2019;33:209–20.
pubmed: 30692207
pmcid: 6362817
Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera R, Sahut-Barnola I, et al. Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS ONE. 2012;7:e44171.
pubmed: 22952916
pmcid: 3429465
Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062–78.
pubmed: 28886379
pmcid: 5743327
Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413–31.
pubmed: 19410540
Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol. 2012;351:101–10.
pubmed: 21930187
Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol. 2012;351:66–70.
pubmed: 22209747
Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni Syndrome Cohort. Cancer. 2016;122:3673–81.
pubmed: 27496084
pmcid: 5115949
Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA. 2001;98:9330–5.
pubmed: 11481490
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–21.
pubmed: 1552940
Park JH, Li J, Starost MF, Liu C, Zhuang J, Chen J, et al. Mouse homolog of the human TP53 R337H mutation reveals its role in tumorigenesis. Cancer Res. 2018;78:5375–83.
pubmed: 30042151
pmcid: 6139041
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
pubmed: 22588877
pmcid: 22588877
Freedman BD, Kempna PB, Carlone DL, Shah M, Guagliardo NA, Barrett PQ, et al. Adrenocortical zonation results from lineage conversion of differentiated zona glomerulosa cells. Dev Cell. 2013;26:666–73.
pubmed: 24035414
pmcid: 3791142
Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000;14:994–1004.
pubmed: 10783170
pmcid: 316543
Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 1999;18:5931–42.
pubmed: 10545105
pmcid: 1171659
Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, et al. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development. 2008;135:2593–602.
pubmed: 18599507
Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995;55:5187–90.
pubmed: 7585571
Pignatti E, Leng S, Yuchi Y, Guagliardo NA, Borges KS, Shah MS, et al. Beta-catenin causes adrenal hyperplasia by blocking zonal transdifferentiation. Cell Rep. 2020;31:107524.
pubmed: 32320669
pmcid: 7281829
Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8:163–9.
pubmed: 6703192
Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré AM, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622–7.
pubmed: 16140927
Terzolo M, Boccuzzi A, Bovio S, Cappia S, De Giuli P, Alì A, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology. 2001;57:176–82.
pubmed: 11164177
Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95:E161–71.
pubmed: 20660055
Leng S, Pignatti E, Khetani RS, Shah MS, Xu S, Miao J, et al. β-Catenin and FGFR2 regulate postnatal rosette-based adrenocortical morphogenesis. Nat Commun. 2020;11:1680.
pubmed: 32245949
pmcid: 7125176
Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91:2650–5.
pubmed: 16670169
Mouat IC, Omata K, McDaniel AS, Hattangady NG, Talapatra D, Cani AK, et al. Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism. Endocr Relat Cancer. 2019;26:217–25.
pubmed: 30475217
pmcid: 7065382
Drelon C, Berthon A, Mathieu M, Ragazzon B, Kuick R, Tabbal H, et al. EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. Hum Mol Genet. 2016;25:2789–800.
pubmed: 27149985
pmcid: 6095221
Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharm. 2010;65:765–73.
Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, et al. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015;21:693–700.
pubmed: 25208878
Zsippai A, Szabó DR, Szabó PM, Tömböl Z, Bendes MR, Nagy Z, et al. mRNA and microRNA expression patterns in adrenocortical cancer. Am J Cancer Res. 2011;1:618–28.
pubmed: 21994902
pmcid: 3189823
Drelon C, Berthon A, Sahut-Barnola I, Mathieu M, Dumontet T, Rodriguez S, et al. PKA inhibits WNT signalling in adrenal cortex zonation and prevents malignant tumour development. Nat Commun. 2016;7:12751.
pubmed: 27624192
pmcid: 5027289
Pereira SS, Monteiro MP, Lacroix A, Pignatelli D. MECHANISMS OF ENDOCRINOLOGY: cell cycle regulation in adrenocortical carcinoma. Eur J Endocrinol. 2018;179:R95–110.
pubmed: 29773584
Mohan D, Lerario AM, Finco I, Hammer G. New strategies for applying targeted therapies to adrenocortical carcinoma. Curr Opin Endocr Metab Res. 2019;8:72–9.
pubmed: 32258822
pmcid: 7133705
Leal LF, Mermejo LM, Ramalho LZ, Martinelli CE Jr, Yunes JA, Seidinger AL, et al. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors. J Clin Endocrinol Metab. 2011;96:3106–114.
pubmed: 21849527
Pinto EM, Rodriguez-Galindo C, Pounds SB, Wang L, Clay MR, Neale G, et al. Identification of clinical and biologic correlates associated with outcome in children with adrenocortical tumors without germline TP53 mutations: a St Jude Adrenocortical Tumor Registry and Children’s Oncology Group Study. J Clin Oncol. 2017;10:3956–63.
Bonnet-Serrano F, Bertherat J. Genetics of tumors of the adrenal cortex. Endocr Relat Cancer. 2018;25:R131–52.
pubmed: 29233839
Batisse-Lignier M, Sahut-Barnola I, Tissier F, Dumontet T, Mathieu M, Drelon C, et al. P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model. Oncogene. 2017;36:4445–56.
pubmed: 28368424
Ahuja D, Sáenz-Robles MT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene. 2005;24:7729–45.
pubmed: 16299533